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GradientIn a recently published paper by Kubo et al. [1], it clearly
documented the interesting biochemical phenomenon of subclin-
ical hemolysis in hypertrophic cardiomyopathy (HCM) patients;
however, it was concerning only a subgroup of patients with the
obstructive form. Importantly for everyday practice, this hemolysis
appears to be associated also with left ventricular outﬂow tract
(LVOT) obstruction only provoked (under stress test) by daily
physical activities. Importantly, although there was no relation
between erythrocyte creatine levels and LVOT gradient in the
subgroup of patients without obstruction at rest (before stress test
induced by the Valsalva provocative maneuver), a correlation
between erythrocyte creatine and LVOT gradient provoked by this
stressor became signiﬁcant in the subgroup of non-obstructive
patients. Summing up, patients with higher erythrocyte creatine
levels exhibited greater LVOT gradient with Valsalva provocation.
These results suggest that intravascular hemolysis is correlated
with severity of LVOT obstruction not at rest but with daily
activities. Importantly as a clinical implication, this biomarker may
be useful for the identiﬁcation of a subgroup of HCM patients with
latent obstruction. In perspective, we may postulate that
measurement of this biomarker appears to be valuable for
monitoring and management of HCM with stable or labile
obstruction.
As regards the potential mechanism of this phenomenon, the
authors postulated several contributors but it was not clariﬁed
which potential variables such as hypertrophied basal ventricular
septum, decreased area of the LVOT, increased ejection velocity,
and elongated mitral valve leaﬂets were responsible for hemolysis.
In previous studies, increased levels of biomarkers of hyper-
coagulation [2] and enhanced oxidative stress [3] are character-
istics of obstructive HCM. Also, acquired type of von Willebrand
disease (type 2A) [4] has been detected. It was proposed that
rapidly turbulent blood ﬂow within LVOT (narrow, irregular canal)
obstruction plays a stimulating role in the activation of various
biomarkers and hematological processes.
Overall, hemostatic effects of LVOT obstruction in HCM may
include procoagulant mechanisms of high shear stress. Both
anatomic (systolic anterior motion of mitral leaﬂet with or without
septal contact) and hemodynamic (pressure gradient) abnormalities
generating turbulent ﬂow might play a role in the prothrombotichttp://dx.doi.org/10.1016/j.jjcc.2015.08.014
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsstate. The precise role of long and thickened mitral leaﬂets
disturbing ﬂow to non-laminar pattern is an important question
for further exploration.
According to Le Tourneau et al. [4], in obstructive HCM, von
Willebrand factor (VWF) impairment is frequent and is closely
related to the magnitude of LVOT obstruction. A resting LVOT
gradient as low as 15 mmHg is sufﬁcient to impair VWF. The
authors’ interpretation of hemodynamic–hematologic phenome-
non is as follows. Given the unique shear stress characteristics of
VWF, it has been postulated that accelerated LVOT velocity at rest
or during exercise might increase proteolysis of VWF multimers
and impair primary hemostasis in the obstructive form of HCM.
The biological effect of LVOT obstruction on VWF function is
detectable in patients with either baseline or latent (exercise-
provoked) obstruction. Primary hemostasis assays that assess VWF
function impairment strongly correlate with the maximal LVOT
gradient and improve with gradient reduction. Primary hemostasis
impairment might favor spontaneous bleeding in patients with an
obstructive form of HCM.
In detail, experimental and biochemical data have demonstrat-
ed that high-shear forces could induce structural changes in the
shape of the VWF molecule, facilitating the action of the speciﬁc
VWF protease ADAMTS 13, which would lead to the loss of the
high-molecular-weight multimer of VWF. In obstructive HCM, this
process may be reversed by therapeutic intervention reducing
LVOT gradient [5]. Importantly, we are able to modify hematologic
abnormalities by reduction of LVOT obstruction. From a practical
point of view, the effective monitoring including biochemical
biomarkers indicating reduction of LVOT gradient is important
because this parameter has become a risk factor for sudden death
in the 2014 ESC guideline [6].
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Biomarkers related to hemodynamic abnormal-
ities with high shear stress
We thank Dr Dimitrow for his interest in our article [1]. In our
paper, we focused on intravascular hemolysis correlated with
severity of left ventricular outﬂow tract (LVOT) obstruction in
hypertrophic cardiomyopathy (HCM) patients [2]. Dr Dimitrow
commented on hematologic characteristics including increased
hypercoagulation, enhanced oxidative stress, and increased
proteolysis of von Willebrand factor (VWF) multimers (acquired
type 2A VW syndrome) in obstructive HCM [1]. Le Tourneau et al.
reported that shear-induced platelet adhesion was impaired in
patients with obstructive HCM, and the ratio of VWF-collagen-
binding activity to antigen and the percentage of high-molecular
weight multimers of VWF were lower in patients with obstructive
HCM than in those with nonobstructive HCM [3]. Furthermore,
platelet adhesion time, VWF-collagen-binding activity-to-antigen
ratio, and the percentage of high-molecular-weight multimers
correlated closely and independently with peak gradient. Acquired
VW syndrome is a recognized risk factor for cutaneous or mucosal
bleeding. From Le Tourneau and colleagues’ observation, obstruc-
tive HCM patients appear to have abnormal spontaneous bleeding
[3].
This phenomenon is also known to be seen in patients with
aortic valve stenosis (AS). The hemorrhagic complication, Heyde’s
syndrome, can occur particularly due to gastrointestinal angio-
dysplasia in AS patients [4], and high shear stress like stenotic
valve is considered to induce structural changes in the shape of the
VWF molecule. According to Vincentelli et al., platelet-function
abnormalities under condition of high shear stress, decreased VWFcollagen-binding activity, and the loss of the largest multimers, or a
combination of these was present in 67–92% of patients with
severe AS and correlated signiﬁcantly with the severity of valve
stenosis [5]. Interestingly, these hemostatic abnormalities were
improved by valve replacement in the absence of mismatch
between patient and prosthesis. Similarly, in obstructive HCM,
treatment led to a substantial decrease in peak gradient associated
with an improvement in VWF-related hemostasis as Le Tourneau
reported [3].
In our paper, we measured erythrocyte creatine, a sensitive and
quantitative marker for intravascular hemolysis, to examine the
presence of subclinical hemolysis and the relation between
intravascular hemolysis and intraventricular pressure gradient
in HCM patients, and found that there was biochemical evidence of
subclinical hemolysis, and this hemolysis appeared to be
associated with LVOT obstruction provoked by daily physical
activities [1]. In patients with HCM, estimation of LVOT gradient is
an important issue because it is related to poor outcome. These
biochemical assessments may become useful surrogate markers
for the existence of LVOT obstruction.
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